SignatureFD
BHVN icon

SignatureFD’s Biohaven BHVN Stock Holding History

SignatureFD’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.12K Buy
309
+108
+54% +$1.56K ﹤0.01% 3002
2026
Q2 		$2.99K Sell
201
-219
-52% -$2.36K ﹤0.01% 3035
2026
Q1 		$3.55K Sell
420
-88
-17% -$963 ﹤0.01% 2890
2025
Q4 		$5.74K Buy
508
+79
+18% +$979 ﹤0.01% 2642
2025
Q3 		$6.44K Buy
429
+260
+154% +$3.78K ﹤0.01% 2567
2025
Q2 		$2.38K Sell
169
-26
-13% -$463 ﹤0.01% 2819
2025
Q1 		$4.69K Buy
195
+33
+20% +$1.16K ﹤0.01% 2628
2024
Q4 		$6.05K Buy
162
+3
+2% +$140 ﹤0.01% 2533
2024
Q3 		$7.94K Buy
159
+4
+3% +$156 ﹤0.01% 2428
2024
Q2 		$5.38K Sell
155
-42
-21% -$1.66K ﹤0.01% 2487
2024
Q1 		$10.8K Buy
197
+6
+3% +$297 ﹤0.01% 2272
2023
Q4 		$8.18K Buy
191
+26
+16% +$809 ﹤0.01% 2343
2023
Q3 		$4.29K Buy
165
+17
+11% +$353 ﹤0.01% 2545
2023
Q2 		$3.54K Sell
148
-2
-1% -$34 ﹤0.01% 2629
2023
Q1 		$2.05K Sell
150
-29
-16% -$462 ﹤0.01% 2797
2022
Q4 		$2.48K Buy
+179
New +$2.53K ﹤0.01% 2735

Other funds holding BHVN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $121B AUM 21.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Royalty Pharma Sub-Manager
Royalty Pharma Sub-Manager New York $196M AUM 16.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

SignatureFD's BHVN Position: Q3 2026 in Review

SignatureFD increased its Biohaven (BHVN) stake by 54% in Q3 2026, buying an estimated $1.56K and bringing the position to 309 shares worth $4.12K. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

SignatureFD first reported a position in BHVN in Q4 2022 and has held it in 16 quarters since. The position peaked at $10.8K in Q1 2024. 216 funds tracked by Wall St. Rank hold BHVN as of Q3 2026.

  • SignatureFD held 309 shares of Biohaven worth $4.12K as of Q3 2026.
  • SignatureFD bought 108 Biohaven shares in Q3 2026, an estimated $1.56K.
  • Biohaven made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3002 holding.
  • SignatureFD first reported a position in Biohaven in Q4 2022 and has held it in 16 quarters since.
  • SignatureFD's Biohaven position peaked at $10.8K in Q1 2024.
  • 216 funds tracked by Wall St. Rank held Biohaven as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.